Fernando Carreno

Fernando Carreno

Auto-generated profile, based on publicly available information

Fernando Carreno

GSK Upper Providence Pennsylvania USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
FGFabiana Rodrigues Silva Gasparin
Fabiana Rodrigues Silva Gasparin
FCFernando Olinto Carreño
Fernando Olinto Carreño
JMJuliana Moraes Mewes
Juliana Moraes Mewes
EGEduardo Hideo Gilglioni
Eduardo Hideo Gilglioni
CPClairce Luzia Salgueiro Pagadigorria
Clairce Luzia Salgueiro Pagadigorria
EIEmy Luiza Ishii Iwamoto
Emy Luiza Ishii Iwamoto

7 March 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
FCFernando Carreño
Fernando Carreño
KPKarina Paese
Karina Paese
CSCarolina Miranda Silva
Carolina Miranda Silva
SGSilvia Guterres
Silvia Guterres
TCTeresa Dalla Costa
Teresa Dalla Costa

18 May 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JGJacqueline G. Gerhart
Jacqueline G. Gerhart
FCFernando O. Carreño
Fernando O. Carreño
MLMatthew Shane Loop
Matthew Shane Loop
CLCraig R. Lee
Craig R. Lee
AEAndrea Edginton
Andrea Edginton
TCthe Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Dosing guidance for children with obesity is often unknown despite the fact that nearly 20% of US children are classified as obese. Enoxaparin, a commonly prescribed low‐molecular‐weight heparin, is dosed based on body weight irrespective of obesity status to achieve maximum concentration within a narrow therapeutic or prophylactic target range. However, whether children with and without obesity experience equivalent enoxaparin exposure remains unclear. To address this clinical question, 2,825 anti–activated factor X (anti‐Xa) surrogate concentrations were collected from the electronic health records of 596 children, including those with obesity. Using linear mixed‐effects regression models, we observed that 4‐hour anti‐Xa concentrations were statistically significantly different in children with and without obesity, even for children with the same absolute dose (P = 0.004). To further mechanistically explore obesity‐associated differences in anti‐Xa concentration, a pediatric physiologically‐based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity. This PBPK model incorporated binding of enoxaparin to antithrombin to form anti‐Xa and elimination via heparinase‐mediated metabolism and glomerular filtration. Following scaling, the PBPK model predicted real‐world pediatric concentrations well, with an average fold error (standard deviation of the fold error) of 0.82 (0.23) and 0.87 (0.26) in children with and without obesity, respectively. PBPK model simulations revealed that children with obesity have at most 20% higher 4‐hour anti‐Xa concentrations under recommended, total body weight–based dosing compared to children without obesity owing to reduced weight‐normalized clearance. Enoxaparin exposure was better matched across age groups and obesity status using fat‐free mass weight‐based dosing.

1 February 2016 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
FCFernando Carreño
Fernando Carreño
KPKarina Paese
Karina Paese
CSCarolina Miranda Silva
Carolina Miranda Silva
SGSilvia Guterres
Silvia Guterres
TCTeresa Dalla Costa
Teresa Dalla Costa

23 October 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
AJAntonio Sueiti Maeda Júnior
Antonio Sueiti Maeda Júnior
JCJorgete Constantin
Jorgete Constantin
KUKarina Sayuri Utsunomiya
Karina Sayuri Utsunomiya
EGEduardo Hideo Gilglioni
Eduardo Hideo Gilglioni
FGFabiana Rodrigues Silva Gasparin
Fabiana Rodrigues Silva Gasparin
RCRodrigo Polimeni Constantin
Rodrigo Polimeni Constantin
Gluconeogenesis overstimulation due to hepatic insulin resistance is the best-known mechanism behind elevated glycemia in obese subjects with hepatic steatosis. This suggests that glucose production in fatty livers may differ from that of healthy livers, also in response to other gluconeogenic determinant factors, such as the type of substrate and modulators. Thus, the aim of this study was to investigate the effects of these factors on hepatic gluconeogenesis in cafeteria diet-induced obese adult rats submitted to a cafeteria diet at a young age. The livers of the cafeteria group exhibited higher gluconeogenesis rates when glycerol was the substrate, but lower rates were found when lactate and pyruvate were the substrates. Stearate or glucagon caused higher stimulations in gluconeogenesis in cafeteria group livers, irrespective of the gluconeogenic substrates. An increased mitochondrial NADH/NAD+ ratio and a reduced rate of 14CO2 production from [14C] fatty acids suggested restriction of the citric acid cycle. The higher glycogen and lipid levels were possibly the cause for the reduced cellular and vascular spaces found in cafeteria group livers, likely contributing to oxygen consumption restriction. In conclusion, specific substrates and gluconeogenic modulators contribute to a higher stimulation of gluconeogenesis in livers from the cafeteria group.

14 May 1999 in Physiology & Behavior
Verified
Journal Article
Closed access
SESergio Espinoza
Sergio Espinoza
TPTeresa Pinto–Hamuy
Teresa Pinto–Hamuy
CPClaudia Passig
Claudia Passig
FCFernando Carreño
Fernando Carreño
FMFernando Marchant
Fernando Marchant
CUChristián Urzúa
Christián Urzúa